BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/19/2015 5:46:00 PM | Browse: 1070 | Download: 1405
 |
Received |
|
2014-08-26 09:02 |
|
Peer-Review Started |
|
2014-08-26 17:19 |
|
To Make the First Decision |
|
2014-09-28 12:27 |
|
Return for Revision |
|
2014-09-29 15:34 |
|
Revised |
|
2014-10-26 11:32 |
|
Second Decision |
|
2015-01-14 08:24 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2015-01-20 16:46 |
|
Articles in Press |
|
2015-01-20 16:46 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2015-01-27 15:43 |
|
Typeset the Manuscript |
|
2015-04-13 16:41 |
|
Publish the Manuscript Online |
|
2015-04-19 17:46 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gan-Lu Deng, Shan Zeng and Hong Shen |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Nature Science Foundation of China |
30770971 |
| National Nature Science Foundation of China |
30800518 |
| National Nature Science Foundation of China |
81070362 |
| National Nature Science Foundation of China |
81172470 |
| National Nature Science Foundation of China |
81372629 |
| key project from the Nature Science Foundation of Hunan Province |
11JJ2049 |
| key project from the Nature Science Foundation of Hunan Province, |
12JJ3118 |
|
| Corresponding Author |
Hong Shen, Professor, Institute of Medical Sciences, Xiangya Hospital, Central South University, No 87, Xiangya Road, Changsha 410008, Hunan Province,
China. hongshen2000@yahoo.com
|
| Key Words |
Hepatocellular carcinoma; Ramucirumab; Regorafenib; Tivantinib; Molecular targeted therapy; Sorafenib; Linifanib; Erlotinib; Everolimus; Sunitinib; Brivanib |
| Core Tip |
Sorafenib is the first drug and now the only systemic treatment to prolong overall survival benefit in patients with hepatocellular carcinoma. In recent years, many molecular targeted agents have been developed and tested. This review article aims to summarize the efforts of systemic therapeutic options and explore the potential new systemic options for this disease.
|
| Publish Date |
2015-04-19 17:46 |
| Citation |
Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol 2015; 7(5): 787-798 |
| URL |
http://www.wjgnet.com/1948-5182/full/v7/i5/787.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v7.i5.787 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
